These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 20836132

  • 1. Whether to target single or multiple CDKs for therapy? That is the question.
    Węsierska-Gądek J, Maurer M, Zulehner N, Komina O.
    J Cell Physiol; 2011 Feb; 226(2):341-9. PubMed ID: 20836132
    [Abstract] [Full Text] [Related]

  • 2. Novel potent pharmacological cyclin-dependent kinase inhibitors.
    Węsierska-Gądek J, Chamrád I, Kryštof V.
    Future Med Chem; 2009 Dec; 1(9):1561-81. PubMed ID: 21425979
    [Abstract] [Full Text] [Related]

  • 3. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
    Orzáez M, Gortat A, Mondragón L, Bachs O, Pérez-Payá E.
    ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
    [Abstract] [Full Text] [Related]

  • 4. [Cyclin-dependent kinase inhibitors in mammal cells].
    Jiang H, Wang YC.
    Sheng Li Ke Xue Jin Zhan; 1996 Apr; 27(2):107-12. PubMed ID: 9592231
    [Abstract] [Full Text] [Related]

  • 5. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1.
    Korkolopoulou P, Christodoulou P, Konstantinidou AE, Thomas-Tsagli E, Kapralos P, Davaris P.
    Hum Pathol; 2000 Jun; 31(6):751-60. PubMed ID: 10872671
    [Abstract] [Full Text] [Related]

  • 6. Multiple functions of p27(Kip1) and its alterations in tumor cells: a review.
    Sgambato A, Cittadini A, Faraglia B, Weinstein IB.
    J Cell Physiol; 2000 Apr; 183(1):18-27. PubMed ID: 10699962
    [Abstract] [Full Text] [Related]

  • 7. Cyclins and related kinases in cancer cells.
    Malumbres M.
    J BUON; 2007 Sep; 12 Suppl 1():S45-52. PubMed ID: 17935277
    [Abstract] [Full Text] [Related]

  • 8. p27: a pleiotropic regulator of cellular phenotype and a target for cell cycle dysregulation in cancer.
    Desdouets C, Bréchot C.
    Pathol Biol (Paris); 2000 Apr; 48(3):203-10. PubMed ID: 10858954
    [Abstract] [Full Text] [Related]

  • 9. Deregulated expression of cell-cycle proteins during premalignant progression in SENCAR mouse skin.
    Rodriguez-Puebla ML, LaCava M, Gimenez-Conti IB, Johnson DG, Conti CJ.
    Oncogene; 1998 Oct 29; 17(17):2251-8. PubMed ID: 9811455
    [Abstract] [Full Text] [Related]

  • 10. The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications.
    Węsierska-Gądek J, Kramer MP.
    Expert Opin Investig Drugs; 2011 Dec 29; 20(12):1611-28. PubMed ID: 22017180
    [Abstract] [Full Text] [Related]

  • 11. Regulation of expression and activity of distinct pRB, E2F, D-type cyclin, and CKI family members during terminal differentiation of P19 cells.
    Gill RM, Slack R, Kiess M, Hamel PA.
    Exp Cell Res; 1998 Oct 10; 244(1):157-70. PubMed ID: 9770359
    [Abstract] [Full Text] [Related]

  • 12. Cell cycle control in breast cancer cells.
    Caldon CE, Daly RJ, Sutherland RL, Musgrove EA.
    J Cell Biochem; 2006 Feb 01; 97(2):261-74. PubMed ID: 16267837
    [Abstract] [Full Text] [Related]

  • 13. P16Ink4a tumor suppressor function in lung cancer cells involves cyclin-dependent kinase 2 inhibition by Cip/Kip protein redistribution.
    Grimison B, Langan TA, Sclafani RA.
    Cell Growth Differ; 2000 Oct 01; 11(10):507-15. PubMed ID: 11063124
    [Abstract] [Full Text] [Related]

  • 14. Anti-sense oligonucleotide of p21(waf1/cip1) prevents interleukin 4-mediated elevation of p27(kip1) in low grade astrocytoma cells.
    Liu J, Estes ML, Drazba JA, Liu H, Prayson R, Kondo S, Jacobs BS, Barnett GH, Barna BP.
    Oncogene; 2000 Feb 03; 19(5):661-9. PubMed ID: 10698511
    [Abstract] [Full Text] [Related]

  • 15. Expression of positive and negative regulators of cell cycle during wound healing.
    Zhu X, Di Y, Hu C, Wang Z.
    Chin Med J (Engl); 2002 Mar 03; 115(3):326-30. PubMed ID: 11940356
    [Abstract] [Full Text] [Related]

  • 16. Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions.
    Klein MA.
    Adv Protein Chem Struct Biol; 2020 Mar 03; 121():115-141. PubMed ID: 32312419
    [Abstract] [Full Text] [Related]

  • 17. Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Blachly JS, Byrd JC, Grever M.
    Semin Oncol; 2016 Apr 03; 43(2):265-73. PubMed ID: 27040705
    [Abstract] [Full Text] [Related]

  • 18. Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.
    Wesierska-Gadek J, Schmid G.
    Expert Opin Investig Drugs; 2006 Jan 03; 15(1):23-38. PubMed ID: 16370931
    [Abstract] [Full Text] [Related]

  • 19. Cyclin-dependent kinase modulators and cancer therapy.
    Gallorini M, Cataldi A, di Giacomo V.
    BioDrugs; 2012 Dec 01; 26(6):377-91. PubMed ID: 22928661
    [Abstract] [Full Text] [Related]

  • 20. Peptides or small molecules? Different approaches to develop more effective CDK inhibitors.
    Cirillo D, Pentimalli F, Giordano A.
    Curr Med Chem; 2011 Dec 01; 18(19):2854-66. PubMed ID: 21651493
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.